Augmenting tumor sensitive matching flow to improve detection and segmentation of ovarian cancer metastases within a PDE framework

Summary: Peritoneal lesions are a relatively common site of metastases, particularly from tumors of the abdomen and pelvis, which generally carry a poor prognosis, often with a signicant impact on treatment. One of the tumors implicated in peritoneal metastasis is ovarian cancer. Ovarian cancer is the fth most commonly diagnosed cancer among women worldwide and the second most common gynecologic malignancy. Despite clinical screening, ovarian cancer in more than 60% of those affected is diagnosed at an advanced stage with a reported 5-year survival rate of 37% (stage III disease) or 25% (stage III disease). IV). Therefore, ovarian cancer is one of the deadliest cancers affecting women. Ovarian tumors are classied according to the origin of the tumor into epithelial tumors (serous and mucinous tumors, endometrioid and clear cell carcinomas, Brenner's tumor), germ cell tumors (mature and immature teratomas, dysgerminoma, endodermal sinus tumor, carcinoma embryonic), sex cord - stromal tumors (brothecoma; granulosa cell, sclerosing stroma and Sertoli-Leydig cell tumors) and metastatic tumors. Metastases to the ovary are relatively common with a documented incidence of 5% to 30% of all malignant ovarian masses. Ovarian cancer metastases differ from other tumors: they are primarily peritoneal rather than parenchymal in location. These implants are usually isodense in tomography, in relation to the viscera, which makes their detection difcult. For this, a multidisciplinary approach is used, such as physical examination, tumor marker levels and diagnostic images. Such as CT, magnetic resonance imaging (MRI) and positron emission tomography (PET). Objective: Describes ovarian metastasis in a patient with no signicant history, emphasizing peritoneal lesions, through a clinical case. Design: Prospective, observational in a single center. Methodology: This is a systematic review of ovarian metastasis, detailing its clinical characteristics and short-term complications. The information and images obtained belong to the medical personnel in charge of the case, whose reinforcements are provided by the Excel, Word and JPG statistical package.

Download Full-text

Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases

10.1158/1538-7445.am2015-455 ◽

2015 ◽

Author(s):

Anne Montfort ◽

Steffen Boehm ◽

Thomas Dowe ◽

Joanne Topping ◽

Michelle Lockley ◽

...

Keyword(s):

Ovarian Cancer ◽

Immune Response ◽

B Cells ◽

High Grade ◽

Serous Ovarian Cancer ◽

Cancer Metastases ◽

Anti Cancer

Download Full-text

Disrupting Ovarian Cancer Metastatic Colonization: Insights from Metastasis Suppressor Studies

Journal of Oncology ◽

10.1155/2010/286925 ◽

2010 ◽

Vol 2010 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Shaheena Khan ◽

Jennifer L. Taylor ◽

Carrie W. Rinker-Schaeffer

Keyword(s):

Ovarian Cancer ◽

Residual Disease ◽

Local Treatment ◽

Disease Recurrence ◽

The United States ◽

Metastasis Suppressor ◽

Metastatic Colonization ◽

Cancer Metastases ◽

Progressive Growth ◽

Microscopic Residual Disease

Ovarian cancer affects approximately 25,000 women in the United States each year and remains one of the most lethal female malignancies. A standard approach to therapy is surgical cytoreduction, after which the remaining microscopic residual disease is treated with chemotherapy. The vast majority of patients have disease recurrence, underscoring the crucial need for approaches to control the regrowth, or colonization, of tissues after local treatment. Improved therapies require mechanistic information about the process of metastatic colonization, the final step in metastasis, in which cancer cells undergo progressive growth at secondary sites. Studies of metastasis suppressors are providing insights into events controlling metastatic colonization. This paper reviews our laboratory's approach to the identification, characterization, and functional testing of the JNKK1/MKK4 metastasis suppressor in ovarian cancer metastatic colonization. Specifically, we demonstrate that interaction of ovarian caner cells with the omental microenvironment activates JNKK1/MKK4 resulting in decreased proliferation without affecting apoptosis. The potential role of the omental microenvironment, specifically milky spot structures, is also described. It is our goal to provide this work as a usable paradigm that will enable others to study metastasis suppressors in clinical and experimental ovarian cancer metastases.

Download Full-text